share_log

Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25

Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25

富國銀行將Integra Lifesciences的評級下調至同等權重,將目標股價下調至25美元
Benzinga ·  05/07 08:43

Wells Fargo analyst Vik Chopra downgrades Integra Lifesciences (NASDAQ:IART) from Overweight to Equal-Weight and lowers the price target from $45 to $25.

富國銀行分析師維克·喬普拉將Integra Lifesciences(納斯達克股票代碼:IART)的評級從增持下調至同等,並將目標股價從45美元下調至25美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論